United-Guardian (UG) Q1 2026 earnings summary

Executive summary

• First quarter 2026 sales rose to $2,872,222 from $2,481,127 year-over-year, with net income increasing to $818,902 from $560,895.

• Growth driven by higher sales in both pharmaceuticals and cosmetic ingredients, notably Renacidin and increased purchases by Ashland Specialty Ingredients.

• Settlement income from a contract manufacturer contributed to quarterly income following a facility shutdown in late 2023.

Financial highlights

• Net sales increased 16% year-over-year to $2,872,222.

• Net income rose 46% to $818,902, with EPS up to $0.18 from $0.12.

• Total costs and expenses were $2,229,773, up from $1,870,205.

• Income from operations reached $642,449, up from $610,922.

• Total other income surged to $390,689 from $97,037, including $303,133 in settlement income.

Outlook and guidance

• Optimism for continued sales growth in 2026, supported by resumed distributor purchasing, new distribution agreements, and expanded product lines.